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Background: To evaluate the role of NADPH oxidase-mediated reactive oxygen species (ROS) production in
multiple sclerosis pathogenesis, we examined the effects of apocynin, an NADPH oxidase assembly inhibitor, on
experimental autoimmune encephalomyelitis (EAE).
Methods: EAE was induced by immunization with myelin oligodendrocyte glycoprotein (MOG (35-55)) in C57BL/6
female mice. Three weeks after initial immunization, the mice were analyzed for demyelination, immune cell
infiltration, and ROS production. Apocynin (30 mg/kg) was given orally once daily for the entire experimental
course or after the typical onset of clinical symptom (15 days after first MOG injection).
Results: Clinical signs of EAE first appeared on day 11 and reached a peak level on day 19 after the initial immunization.
The daily clinical symptoms of EAE mice were profoundly reduced by apocynin. The apocynin-mediated inhibition of the
clinical course of EAE was accompanied by suppression of demyelination, reduced infiltration by encephalitogenic
immune cells including CD4, CD8, CD20, and F4/80-positive cells. Apocynin reduced MOG-induced pro-inflammatory
cytokines in cultured microglia. Apocynin also remarkably inhibited EAE-associated ROS production and blood–brain
barrier (BBB) disruption. Furthermore, the present study found that post-treatment with apocynin also reduced the clinical
course of EAE and spinal cord demyelination.
Conclusions: These results demonstrate that apocynin inhibits the clinical features and neuropathological changes
associated with EAE. Therefore, the present study suggests that inhibition of NADPH oxidase activation by apocynin may
have a high therapeutic potential for treatment of multiple sclerosis pathogenesis.
Keywords: Experimental autoimmune encephalomyelitis, Multiple sclerosis, NADPH oxidase, Reactive oxygen species,
Apocynin, MicrogliaBackground
Multiple sclerosis (MS) is one of the most common
neurological disorders and causes of disability in young
adults [1] and is the most common inflammatory de-
myelinating disorder of the central nervous system
(CNS). Hallmarks of MS include multifocal perivascular
mononuclear cell infiltration in the CNS, oligodendro-
cyte loss, blood–brain barrier disruption, and demyelin-
ation. Axonal damage is also seen to occur after primary
demyelination and can lead to permanent neurological
deficits.* Correspondence: swsuh@hallym.ac.kr
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unless otherwise stated.Reactive oxygen species (ROS) are involved in the
pathogenesis of MS and experimental autoimmune en-
cephalomyelitis (EAE) [2, 3]. Increased production of
ROS following EAE is an important underlying cause of
demyelination. Activated NADPH oxidases produce
ROS that are released into the intra- or extracellular
space and contribute to progressive demyelination. Due
to the requirement of protein kinase activity for phos-
phorylation and translocation of NADPH oxidase sub-
units (e.g., p47phox) prior to its activation, this enzyme is
directly regulated by plasma membrane receptors and
signaling pathways [4]. Our previous studies have dem-
onstrated that NADPH oxidase-derived ROS production
modulates neuronal death in hypoglycemia, ischemia,
epilepsy, and traumatic brain injury [5–9].is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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plant Picrorhiza kurroa. Apocynin inhibits NADPH oxi-
dase activation in neutrophils [10, 11], macrophages,
and systemic endothelia [12] through the inhibition of
p47phox subunit translocation. It has been reported that
apocynin protects against global cerebral ischemia-
induced oxidative stress and neuronal injury in the
hippocampus [7, 13], and inhibiting ROS production by
apocynin preserves blood–brain barrier [14]. Van der
Goes et al. demonstrated that the phagocytosis of myelin
by macrophages triggers the production of ROS, which
play a crucial role in myelin phagocytosis. Using periton-
eal macrophage culture, blocking ROS production with
apocynin prevented the phagocytosis of myelin [15]. In
addition, Van der Veen et al. has reported that neutro-
phil cytosolic factor 1 (NCF1, also known as p47phox)
knockout mice are resistant to EAE [16]. However, the
protective effects of apocynin have never been tested
using the mouse model of EAE.
One of the best described and most commonly used
animal models of MS is EAE. EAE is induced by
immunization with myelin oligodendrocyte glycoprotein
(MOG (35-55)) peptide [17, 18]. Using the MOG-induced
EAE mouse model, we investigated if systemically deliv-
ered apocynin could suppress EAE disease progression. In
the present study, we found that apocynin ameliorated the
severity of the EAE in MOG-injected mice, which is ac-
companied by reduction of demyelination and ROS pro-
duction, attenuation of microglial activation, inhibition of
immune cell infiltration, and reduction of BBB disruption.
These data establish inhibition of NADPH oxidase activa-
tion by apocynin as a potential therapeutic strategy in MS.
Methods
Induction of EAE
Animal use and relevant experimental procedures were
approved by the Institutional Animal Care and Use
Committee, Hallym University (Protocol # Hallym 2011-68).
This manuscript was written in accordance with the
ARRIVE (Animal Research: Reporting In Vivo Experiments)
guidelines [19]. C57BL/6 female mice, aged 8 weeks,
purchased from DBL (Chungcheongbuk, Korea) were
housed in a temperature- and humidity-controlled en-
vironment and supplied with Purina diet (Purina,
Gyeonggi, Korea) and water ad libitum. Mice were
immunized on day 0 by subcutaneous injection of 200 μl
of a mixture of recombinant MOG (35-55, 2 mg/ml)
(AnaSpec, CA) and complete Freund’s adjuvant containing
400 μg of Mycobacterium tuberculosis H37RaA (Difco
Laboratories, MI) according to the manufacturer’s instruc-
tion. Pertussis toxin (List Biological Laboratories, CA) was
intraperitoneally administered at a dose of 400 ng on post-
immunization days 0 and 2. A booster injection of MOG
was given on day 7 after the initial immunization.Apocynin administration
Apocynin (Apo, Sigma, St Louis, MO) was dissolved
with DMSO and diluted by a factor of 10 with saline
(10 % DMSO). Apocynin was delivered by gavage once
per day at a dose of 30 mg/kg/day from day 0 until the
end of the experiment. Animals were divided into four
groups to evaluate the pre-treatment effects of apocynin
for short-term period: (1) sham without apocynin (DMSO
only, n = 7), (2) sham with apocynin (apocynin only,
n = 6), (3) EAE without apocynin (EAE +DMSO, n = 12),
and (4) EAE with apocynin (EAE + apocynin, n = 12).
Animals were divided into four groups to evaluate the
pre-treatment effects of apocynin for long-term period: (1)
sham without apocynin (DMSO only, n = 2), (2) sham with
apocynin (apocynin only, n = 2), (3) EAE without apocynin
(EAE +DMSO, n = 6), and (4) EAE with apocynin (EAE +
apocynin, n = 6). To test the post-treatment effects of apoc-
ynin, apocynin was delivered 3 days after the typical onset
of clinical symptoms (15 days after first MOG injection).
Animals were divided into two groups: (1) EAE without
apocynin (EAE +DMSO, n = 5) and (2) EAE with apocynin
(EAE + apocynin, n = 5).
Disease scoring
Behavior was scored daily for evaluation of clinical fea-
tures of EAE according to the following criteria: 0, no
deficit; 0.5, partial loss of tail tone or slightly abnormal
gait; 1.0, complete tail paralysis or both partial loss of tail
tone and mild hind limb weakness; 1.5, complete tail
paralysis and mild hind limb weakness; 2.0, tail paralysis
with moderate hind limb weakness (evidenced by fre-
quent foot dropping between bars of cage top while
walking); 2.5, no weight-bearing on hind limbs (drag-
ging) but with some leg movement; 3.0, complete hind
limb paralysis with no residual movement; 3.5, hind limb
paralysis with mild weakness in forelimbs; 4.0, complete
quadriplegia but with some movement of head; 4.5,
moribund; and 5, dead [20]. General linear models
(GLM) repeated measures were conducted to investigate
differences of clinical scores changing over time among
groups. The maximal clinical scores were also compared
between vehicle- and apocynin-treated EAE animals.
Histological evaluation of the spinal cord and brain
On day 21 after the initial immunization, mice were
transcardially perfused with 4 % paraformaldehyde (PFA)
under urethane anesthesia. The brain and spinal cord
were removed and post-fixed in the same fixative.
Paraffin-embedded sections at 5 μm were made after
embedding in paraffin and then stained with luxol fast
blue (LFB) to detect demyelination. Frozen sections at
30 μm were stained with cresyl violet to determine
mononuclear cell infiltration. To quantify LFB staining
results, five sections from each mouse were examined
Choi et al. Journal of Neuroinflammation  (2015) 12:104 Page 3 of 15from three mice per group. A quantitative analysis of de-
myelination was performed using Adobe Photoshop CS5
(Adobe Systems, Mountain View, CA) extended; images
at the same magnification were straightened. The area of
the entire spinal cord was selected by a lasso tool and
measured as number of pixels displaying positive signal.
Only regions of demyelination were selected, and then
demyelinated area was expressed as % area (demyeli-
nated area/total spinal cord area × 100). The number of
infiltrated mononuclear cells was counted manually
from images under higher magnification by a blinded
observer. The method for quantifying demyelination was
modified from McCully et al. [21].Detection of ROS
For detection of ROS production after EAE, mice were
injected intraperitoneally with 10 mg/kg dihydroethidium
(dHEt) (Molecular Probes, Invitrogen) at 21 days after first
immunization. The dHEt is preferentially oxidized by
superoxide, although it is also sensitive to other reactive
species, providing an index of the production of reactive
species. After its oxidation in the cytosol, dHEt produces
the fluorescent compound ethidium (Et) [22]. Mice were
euthanized 3 h after dHEt injection and transcardially per-
fused with 0.9 % saline followed by 4 % PFA fixation. In
30 μm cryostat sections, Et signals were photographed with
a LSM 710 confocal imaging system (Carl Zeiss, Germany)
with an excitation of 510–550 nm and an emission greater
than 580 nm. Images were taken from the thoracic spinal
cord section. Et signal intensity was measured by image J
(NCBI, MD) and expressed as mean gray value.Immunohistochemical examination of the spinal cord
The spinal cord, previously perfused with 4 % parafor-
maldehyde, was post-fixed in the same fixative overnight
and cryoprotected in PBS containing 30 % sucrose at
4 °C for 2 days. Frozen 30-μm sections of the spinal cord
were immunohistochemically stained with specific anti-
bodies against cell surface molecules for cluster dif-
ferentiation (CD) according to conventional methods.
Monoclonal antibodies against CD4 (BD Bioscience,
CA), CD8 (BD Bioscience), F4/80 (eBioscience, CA)
produced in a rat, or a polyclonal antibody against
CD20 produced in goat (SantaCruz Biotechnology, CA)
were used as the primary antibodies. A secondary anti-
body against rat IgG or goat IgG (Vector, Burlingame,
CA, USA) was used. The immunoreaction was visual-
ized with 3,3′-diaminobenzidine (DAB) after incu-
bation in ABC reagent (Vector, Burlingame, CA).
Finally, they were mounted on 0.5 % gelatin-coated
slides, coverslipped, and photographed with an Olympus
microscope. To assess nonspecific effects, a few sections
in every experiment were incubated in a buffer withoutprimary antibodies. This procedure always resulted in a
complete lack of immunoreactivity.
Reverse transcription polymerase chain reaction analysis
The spinal cord and spleen were perfused with cold PBS,
and extraction of total RNA was performed with the
NucleoSpin® RNA (Macherey-Nagel, Düren, Germany).
Reverse transcription polymerase chain reaction (RT-
PCR) was performed to measure the levels of mRNA
specific for tumor necrosis factor alpha, interleukin-1
beta, and interleukin 12 in the extract according to the
manufacturer’s instructions. First-strand cDNA was syn-
thesized from 1 μg of total RNA using the ReverTra
Ace® qPCR RT Master Mix with gDNA Remover
(Toyobo Corporation, Osaka, Japan) according to the
manufacturer’s instruction. The oligonucleotide primers
were as follows: TNF-α forward 5′-TCT CAT CAG TTC
TAT GGC CC-3′, reverse 5′-GGG AGT AGA CAA
GGT ACA AC-3′; IL-1β forward 5′-TTG ACG GAC
CCC AAA AGA TG-3′, reverse 5′-AGA AGG TGC
TCA TGT CCT CA-3′; IL-12 forward 5′-CAC GCC
TGA AGA AGA TGA CA-3′, reverse 5′-AGT CCC
TTT GGT CCA GTG TG-3′; and β-actin forward 5′-
TGG AAT CCT GTG GCA TCC ATG AAA C-3′,
reverse 5′-TAA AAC GCA GCT CAG TAA CAG TCC
G-3′. RT-PCR products were separated on an agarose
gel, and then RNA bands were quantified using Image J
after staining with ethidium bromide.
Detection of blood–brain barrier disruption by IgG
extravasation
To detect blood–brain barrier disruption, histological ana-
lysis of IgG extravasation was performed with the thoracic
spinal cord of normal or EAE mice at 21 days after first
MOG injection. Free-floating 30 μm coronal sections from
the spinal cord were immunostained with biotinylated
horse anti-mouse IgG (Vector, Burlingame, CA). From the
spinal cord section images, the IgG-stained area was also
measured by Image J. Measurement of the IgG-stained
area was quantified using the method modified from Tang
et al. [23]. Briefly, to quantify the area of IgG leakage, the
image was loaded into Image J and converted into an 8-bit
image. Then, the image was thresholded using the menu
option. The type was set to black and white and the bot-
tom slider set to a value of 106. The resulting thre-
sholded image is binary and will only show the region of
IgG leakage. To measure this area, the menu option
Analyze→Measure was selected. The selected region of
the spinal cord in the whole image was sorted, and then
area of IgG leakage was expressed as % area.
Detection of neutrophil infiltration
To detect neutrophil infiltration in the EAE spinal cord,
sections were incubated in rabbit anti-myeloperoxidase
Choi et al. Journal of Neuroinflammation  (2015) 12:104 Page 4 of 15(MPO, diluted 1:100, Thermo Fisher Scientific, Waltham,
MA) in PBS containing 0.3 % Triton X-100 overnight at
4 °C. After washing three times for 10 min with PBS,
sections were incubated in Alexa Fluor 488 donkey anti-
rabbit IgG antibody (diluted 1:250, Invitrogen, Grand Island,
NY) for 2 h at room temperature. The sections were
washed three times for 10 min with PBS and mounted
on gelatin-coated slides. All images were captured using
a fluorescence microscope (Olympus upright microscope
IX70, Olympus, Shinjuku, Tokyo, Japan). To quantify
MPO staining results, five sections from each mouse were
examined from five mice per group. A blinded observer
counted the total number of MPO-positive cells in region
of interest.
Detection of NADPH oxidase activation
To identify p47phox subunit expression in the EAE spinal
cord, double immunofluorescence staining was performed.
Thoracic spinal cord sections were incubated in mixture of
rabbit anti-p47 (diluted 1:200, Novus, USA)/mouse anti-
microtubule-associated protein 2 (MAP2, diluted 1:200,
Millipore, Billerica, MA) in PBS containing 0.3 % Triton
X-100 overnight at 4 °C. After washing three times for
10 min with PBS, sections were incubated in a mixture of
Alexa Fluor 488 donkey anti-mouse IgG and Alexa Fluor
594 anti-rabbit IgG antibodies (diluted 1:250, Invitrogen,
Grand Island, NY) for 2 h at room temperature. The sec-
tions were washed three times for 10 min with PBS and
mounted on gelatin-coated slides. All images were cap-
tured using a LSM710 confocal microscope (Carl Zeiss,
Germany).
Primary microglia cell culture preparation
Mixed glial cultures were prepared from 1-day-old
mouse pups of both sexes in 24-well plates as described
previously [24]. At confluence, microglia were harvested
by gently shaking and re-plated at a density of 5 × 105
cells/well on a 24-well plate. The microglia cultures were
subsequently maintained in glial conditioned medium
for 24–48 h after which they were used for experiments.
The experimental drugs were all dissolved in Eagles
minimal essential medium (MEM). Bovine serum albu-
min (BSA) was used as a control condition for MOG.
The MOG dose of 3 μg/ml was selected from the dose
range of 1–10 μg/ml because it was the lowest dose to
induce a clear (~50 %) increase in number of morpho-
logically activated microglia, and highest tested doses
did not show a significant increase in their efficacy
(caused ~61 % of microglia to be morphologically acti-
vated). Apocynin was dissolved with DMSO, which re-
sulted in a final concentration of 0.0075 % to be used in
experiments. DMSO is well known to act as a free rad-
ical scavenger, but at low doses, this effect is negligible
(data not shown).Analysis of microglial morphology, transformation, and
proliferation
Microglial morphology and proliferation was determined
by cell assessment and counting in five randomly se-
lected phase contrast microscopic fields per culture well.
Values were normalized to counts in control wells from
the same 24-well plate. Microglia with two or more thin
processes were considered as ramified, resting microglia,
and microglia with less than two processes, or with
amoeboid cell soma, were classified as activated [25].
The numbers of resting and activated microglia were
counted in five randomly selected fields per culture well.
Evaluations in this study were performed by an observer
blinded to the experimental conditions.
Detection of superoxide production in vitro
For 5 μM dHEt, detection was performed every 15 min
within first hour by plate reader with excitation/emission
wavelength of 510/580 nm, respectively. Results are pre-
sented as a fold change from base line dHEt readings
normalized to control condition (BSA) at the peak time
of superoxide production (45–60 min).
Analysis of cytokine release
Cytokine release was analyzed from culture supernatant
collected 24 h after the exposure to MOG by Mouse In-
flammation antibody Array C1 (RayBiotech, Inc.), detecting
40 different pro- and anti-inflammatory cytokines accord-
ing to the manufacturer’s instruction. The cytokine-release
data was normalized to protein levels to balance the mild
proliferation induced by MOG and prevented by apocynin
treatment. The data is presented as a fold change com-
pared to control levels.
Statistical analysis
EAE clinical scores were reported as average ± sem. GLM
repeated measures were conducted to investigate differ-
ences of clinical scores changing over time among groups
using SPSS ver.21. The fluorescence intensity and T cell
proliferation data were expressed as the mean ± sem and
analyzed for statistical significance using a one-way
ANOVA, followed by a Bonferroni post hoc test. Cell
culture data were expressed as the mean ± sem com-
pared with ANOVA followed by the Bonferroni’s test
for multiple group comparisons. p < 0.05 was consid-
ered significant.
Results
Apocynin ameliorates clinical signs and disease progression
of MOG-induced EAE
Mice immunized with MOG (35-55) developed severe
EAE symptoms with complete hind limb paralysis. As
shown in Fig. 1, consecutive administration of apocynin
from the beginning of MOG injection resulted in
Fig. 1 Apocynin ameliorates the clinical signs and disease progression of MOG-induced EAE. Clinical disease scores were recorded daily until
21 days after induction. The clinical signs of EAE first appeared on day 11 and reached peak levels on day 19 from the 1st MOG (M) immunization.
Apocynin (EAE + apocynin, n = 12) or its vehicle (EAE + vehicle, n = 12) was orally administered during the entire period. Control groups also
received oral apocynin (sham + apocynin, n = 6) or vehicle only (sham + vehicle, n = 7) without (N) MOG immunization. a Apocynin profoundly
reduced the EAE clinical score induced by MOG. Data are mean ± sem (n = 6–12). *p < 0.05 compared with apocynin-treated group. General linear
models verified statistically significant differences in clinical scores by time and treatment, and interaction between time and treatment was also
noticed. b Apocynin reduced the incidence rate of EAE induced by MOG. c, d Apocynin reduced MOG-induced demyelination in spinal cord of
EAE mice. Mice were sacrificed 3 weeks after MOG injection, and sections of spinal cord were evaluated for damaged myelin sheaths using luxol
fast blue (LFB). The presence of white matter lesions are reflected by reduced LFB staining in the spinal cord. c LFB staining of the spinal cord
shows extensive demyelination in the MOG-immunized EAE mice. EAE-associated demyelination is almost completely absent in EAE mice treated
with apocynin. The square area in the low magnification view seen in the left-hand panel was enlarged four hundred times and illustrated in the
right-hand panel. Scale bar represents 50 μm. d The graph represents percent of demyelination of white matter of the thoracic spinal cord with
or without apocynin treatment in EAE mice. Data are mean ± sem (n = 3). *p < 0.05 compared with the apocynin-treated group
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rate (Fig. 1b) of EAE. Apocynin treatment decreased
the motor deficit score at 19 days from 2.33 ± 0.22 (of
5 maximum) to 0.67 ± 0.18, a 71.2 % reduction (Fig. 1a).
General linear models verified statistical significant
differences in clinical scores by time (F = 23.648,
p < .001) and treatment (F = 28.793, p < .001), and inte-
raction between time and treatment was also noticed
(F = 16.722, p < .001).Apocynin reduces MOG-induced white matter damage in
the spinal cord of EAE mice
LFB staining of the spinal cord revealed extensive de-
myelination in the MOG-immunized EAE mice (Fig. 1c).
In contrast, apocynin-treated EAE mice showed much
less demyelination. Compared with the vehicle-treated
EAE group, the apocynin-treated EAE group had a
61.6 % reduction in demyelination in the examined
spinal cord sections (Fig. 1d).
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To test whether ROS production occurred after MOG
immunization in the spinal cord, mice were injected
with dHEt at 21 days after first immunization and then
spinal cords were harvested 3 h after dHEt injection.
ROS production was detected in the thoracic spinal
cord by Et signal. Sham-operated mice represented less
Et fluorescence intensity. MOG-immunized EAE mice
showed remarkable increase of Et signal in the white
matter of the spinal cord (Fig. 2a, b). However,
apocynin-treated EAE mice showed reduced Et fluores-
cence intensity. Compared with the vehicle-treated
EAE group, the apocynin-treated EAE group had a
66.17 % reduction in ROS production in the examined
spinal cord sections (Fig. 2c).Fig. 2 MOG-induced ROS production and p47phox expression are reduc
dHEt fluorescence staining 21 days after the first immunization. Mice w
n = 3) showed substantially increased Et fluorescence intensity in the w
treatment showed substantial reduction of this Et fluorescence intensit
a was enlarged four hundred times and illustrated in the right-hand panel. Sc
as mean gray value (Image J). Data are mean ± sem (n = 3). *p < 0.05 com
treatment influences NADPH oxidase activation in EAE mice, NADPH oxidase
stained. Sham-operated spinal cord section showed only weak p47phox expres
the spinal cord 21 days after MOG injections (EAE + vehicle, n = 3). Howev
(EAE + apocynin, n = 3) in EAE mice. e The square area in the low magnific
the right-hand panel. Scale bar represents 50 μm. f The graph represents
mean ± sem (n = 3). *p < 0.05 compared with apocynin-treated groupMOG-induced NADPH oxidase subunit expression is
reduced by apocynin
To test whether apocynin treatment influences NADPH
oxidase activation in EAE mice, we used double immuno-
fluorescence (Fig. 2d, e). Compared to sham-operated
control, the spinal cord of MOG-immunized EAE group
showed increased p47phox intensity. Apocynin treatment
decreased p47phox fluorescence intensity in EAE mice,
which represents inhibition of NADPH oxidase activation
in EAE mice.
Decreased mononuclear cell infiltration in apocynin-treated
EAE mice
EAE mice displayed intensive infiltration of mono-
nuclear cells around the white matter of the spinal corded by apocynin. ROS production in the spinal cord was detected by
ere sacrificed 3 h after dHEt injection. a EAE mice (EAE + vehicle,
hite matter of the spinal cord. Apocynin (EAE + apocynin, n = 3)
y in EAE mice. b The square area in the low magnification of panel
ale bar represents 50 μm. c The graph represents Et fluorescence intensity
pared with the apocynin-treated group. d To test whether apocynin
subunit (p47phox) and neurons (MAP2) were immunohistochemically
sion. A prominent increase in p47phox expression was seen throughout
er, the expression of p47phox was reduced by apocynin treatment
ation of d panel was enlarged four hundred times and illustrated in
p47phox fluorescence intensity as mean gray value (Image J). Data are
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in Fig. 3 show markedly reduced infiltration of mono-
nuclear cells in sections of the spinal cord and cerebel-
lum derived from apocynin-treated EAE mice compared
with vehicle-treated EAE mice.
Apocynin modulates microglial responses to MOG
The effects of apocynin in EAE mice were further evalu-
ated in primary microglia cultures stimulated with MOG.
Marked increase in transformation towards amoeboid
morphology, proliferation, superoxide production, and
pro-inflammatory cytokine release (IFNɣ, IL-1α, IL-1β,
and TNFα) was induced by 3 μg/ml MOG. MOG induced
a significant increase in the release of pro-inflammatory
cytokines. Apocynin prevented these effects of MOG and
sifted cytokine release pattern towards anti-inflammatory
phenotype by significantly promoting IL-4 release and
decreasing pro-inflammatory cytokines (Fig. 4a–d).Fig. 3 Apocynin treatment attenuates MOG-induced mononuclear cell infiltra
weeks after the initial immunization of MOG, infiltration of mononuclear cells
cresyl violet staining. EAE mice (EAE + vehicle, n = 3) revealed intensive infiltra
and cerebellum (c). However, apocynin treatment (EAE + apocynin, n = 3) redu
Scale bar represents 200 μm. The graphs represent number of infiltrated cells
without apocynin treatment in sham-operated and EAE mice. Data are meanApocynin suppresses T cell, B-lymphocyte, and microglial
infiltration in EAE mice
The above results were further confirmed by immunohis-
tochemical staining for CD4+ T, CD8+ T, and CD20+ B
lymphocytes. Spinal cords derived from EAE mice were
rich in CD4+ T, CD8+ T, and CD20+ B cell infiltrates,
while treatment with apocynin significantly decreased
CD4+ T, CD8+ T, and CD20+ B cell infiltrates into the
white matter. F4/80 expression was apparently increased
on day 21 post-MOG immunization. In contrast, a signifi-
cantly reduced number of F4/80 stained cells were present
after apocynin treatment (Fig. 5a, b).
Apocynin suppresses production of pro-inflammatory
cytokines in the spleen and spinal cord of EAE mice
To test whether apocynin treatment influences production
of pro-inflammatory cytokines in EAE mice, we measured
the levels of mRNA specific for tumor necrosis factortion into white matter of spinal cord and cerebellum in mice. Three
around small vessels in the spinal cord and cerebellum was detected with
tion of mononuclear cells around the white matter of the spinal cord (a)
ced mononuclear cell infiltration into the white matter of the spinal cord.
in the white matter of thoracic spinal cord (b) and cerebellum (d) with or
± sem (n = 3). *p < 0.05 compared with apocynin-treated group
Fig. 4 Apocynin modulates microglial responses to MOG. MOG (3 μg/ml) induced morphological transformation of microglia towards amoeboid
morphology (a) and increased cell counts (b) suggesting proliferation within 24 h from stimulation. c The superoxide production was measured within
an hour after the MOG stimuli. Apocynin (Apo, 600 μM) treatment prevented these microglial responses to MOG stimulation and also reduced basal
response levels. Bovine serum albumin (3 μg/ml) was utilized as a control (Ctrl). The graphs show the quantitation of the data. The units shown in B
and C are reported as fold changes compared to Ctrl. Data are mean ± sem (n = 4-5) *p < 0.05, #p < 0.05 compared with Ctrl group. d Cytokine analysis
demonstrate that MOG increases release of pro-inflammatory cytokines such as IFNɣ, IL-1α, IL-1β, and TNFα and reduces release of anti-inflammatory
cytokine such as IL-4, while apocynin treatment reduced pro-inflammatory cytokine release and promoted anti-inflammatory IL-4 release. The units are
reported as fold changes compared to Ctrl. Data are mean ± sem (n= 3) *p < 0.05, #p < 0.05 compared with Ctrl group
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and spinal cord. RT-PCR analysis exhibited that mRNA of
TNF-α, IL-12, and IL-1β were highly upregulated in the
spleen and spinal cord of EAE mice. Apocynin-treated
EAE mice showed significantly inhibited production of
TNF-α and IL-12 mRNA in the spleen and TNF-α mRNA
in the spinal cord. However, IL-1β mRNA was not seen to
differ between vehicle- and apocynin-treated groups in the
spleen and spinal cord of EAE mice (Fig. 5c–f ).Apocynin reduces MOG-induced blood–brain barrier
disruption
To evaluate the putative damage of the BBB, we looked
for leakage of serum IgGs using immunohistochemistry.
Compared with sham-operated control, there was a
significant increase in IgG extravasation observed in
the thoracic spinal cord at 21 days after first MOG
immunization. Compared to the vehicle-treated EAE
mice, apocynin-treated EAE mice showed significantly
reduced IgG extravasation (Fig. 6a, b).Decreased MPO-positive cell infiltration in apocynin-treated
EAE mice
To test whether neutrophil infiltration occurred after
MOG immunization, spinal cord sections were mea-
sured by myeloperoxidase (MPO) infiltration [26, 27].
MPO is a heme protein synthesized during myeloid
differentiation that constitutes the major component
of neutrophil azurophilic granules [28]. While MPO
is predominantly released by neutrophils, monocyte
lineage cells are also capable of secreting MPO [29].
EAE mice showed intensive infiltration of neutrophils
around the white matter of spinal cord (Fig. 6c, d).
Results presented show markedly reduced infiltration
of neutrophils in the spinal cord derived from apocynin-
treated EAE mice compared with vehicle-treated EAE
mice.
Long-term protective effects of apocynin after EAE
To test whether chronic apocynin treatment is also
effective against EAE disease progression, apocynin
was administered by gavage once per day for 45 days
Fig. 5 (See legend on next page.)
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Fig. 5 Apocynin treatment attenuates MOG-induced immune cell infiltration in the spinal cord and production of pro-inflammatory cytokines in
the spleen and spinal cord. a PFA-fixed sections of the thoracic spinal cord were immunohistochemically stained with antibodies against cell
surface molecules such as CD4, CD8, F4/80, and CD20. Immunostaining revealed that T cell, B cell, and microglia/macrophage-labeled cells were
extensively infiltrated into the white matter of the spinal cord in EAE mice (EAE + vehicle, n = 3). However, apocynin treatment reduced the
infiltration of immune cells into the white matter of the spinal cords in EAE mice (EAE + apocynin, n = 3). Scale bar represents 200 μm. b The
graphs represent percent area of CD4, CD8, F4/80, and CD20 immunoreactivity in the white matter of thoracic spinal cord with or without
apocynin treatment in sham-operated and EAE mice. Data are mean ± sem (n = 3). *p < 0.05 compared with apocynin-treated group. Spleen and
spinal cord perfused with cold PBS were used for extraction of total RNA. Expression of mRNA was determined with the RT-PCR method. RT-PCR
results demonstrated an increase of TNF-α and IL-12 in the spleen (c) and spinal cord (e) of EAE mice (EAE + vehicle, n = 4). However, apocynin
(EAE + apocynin, n = 4) significantly reduced the EAE-associated increase in mRNA expression of TNF-α and IL-12. The graphs represent quantification
of TNF-α and IL-12 expression with or without apocynin treatment in the spleen (d) and spinal cord (f) of EAE mice. Data are mean ± sem (n = 4).
*p < 0.05 compared with apocynin-treated group
Fig. 6 Apocynin reduces blood–brain barrier disruption and neutrophil infiltration in the white matter of EAE spinal cord. a Images represent
immunohistochemical characterization of IgG extravasation in the thoracic spinal cord of EAE mice. Sham-operated spinal cord section showed
only weak IgG immunoreactivity (IR) primarily confined to the BBB-deficient area. Some perivascular extravasation of IgG (brown color) was
detected in the thoracic spinal cord of normal mice. Prominent extravasation of IgG is seen throughout the parenchyma of the spinal cord 21 days
after MOG injections (EAE + vehicle, n = 3). However, the extensive diffusion of IgG IR was reduced by apocynin treatment in EAE mice (EAE +
apocynin, n = 3). Scale bar represents 200 μm. b The graph represents percent area of IgG IR in the white matter of thoracic spinal cord with or
without apocynin treatment in sham-operated and EAE mice. Data are mean ± sem (n = 3). *p < 0.05 compared with apocynin-treated group. c
Fluorescence images display neutrophil infiltration by myeloperoxidase (MPO) staining in the spinal cord. EAE mice (EAE + vehicle, n = 5) revealed
intensive infiltration of neutrophil in the white matter of the spinal cord. However, apocynin treatment reduced neutrophil infiltration into the
white matter of spinal cord in EAE mice (EAE + apocynin, n = 5). Scale bar represents 100 μm. d The bar graph shows the quantification of
MPO(+) cells in the spinal cord. The number of MPO(+) cells is significantly different between vehicle (Veh)- and apocynin (Apo)-treated group in
the EAE mice. Data are mean ± sem (n = 5). *p < 0.05 compared with apocynin-treated group
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the short-term treatment experiments, chronic treat-
ment with apocynin also reduced the clinical score
and histological findings. As shown in Fig. 1, long-
treatment with apocynin also produced improvement
in the clinical score and reduced demyelination in the
EAE animals. Apocynin treatment decreased the motor
deficit score at 20 days from 2.3 ± 0.34 (of 5 maximum)
to 0.8 ± 0.21, a 66.7 % reduction (Fig. 7a). General linear
models verified statistically significant differences in
clinical scores by time (F = 10.482, p < .001) and treat-
ment assignment (F = 13.750, p < .001), and interaction
between time and treatment assignment was also noticed
(F = 5.511, p < .001). And apocynin treatment also
decreased demyelination (Fig. 7c). Furthermore, this
preservation of the clinical score was evident until at
least 45 days after first MOG immunization.Fig. 7 Long-term protective effects of apocynin after EAE induction. Clinica
clinical signs of EAE first appeared on day 14 and reached peak levels on d
n = 6) or its vehicle (EAE + vehicle, n = 6) was orally administered during
(sham + apocynin, n = 2) or vehicle only (sham + vehicle, n = 2) without
clinical score induced by MOG. Data are mean ± sem (n = 2–6). *p < 0.05
verified statistical significant differences in clinical scores by time and tre
noticed. b Apocynin did not influence the rate of EAE induction by MOG. c LF
MOG-immunized EAE mice. EAE-associated demyelination is almost comp
the low magnification of the left-hand panel was enlarged two times andPost-treatment of apocynin also decreases clinical signs
and histological progress of EAE
To test whether post-treatment of apocynin is also ef-
fective on EAE disease progression, apocynin was deliv-
ered 3 days after the typical onset of clinical symptoms
(18 days after MOG injection). As shown in the above
experiments, post-treatment of apocynin also reduced
the clinical score and histological findings. As shown in
Fig. 1, post-treatment with apocynin also produced im-
provement in the clinical score and reduced demyelin-
ation of EAE animals. Apocynin treatment decreased the
motor deficit score at 22 days from 3.4 ± 0.21 (of 5 max-
imum) to 2.1 ± 0.33, a 38.24 % reduction (Fig. 8a).
General linear models verified statistically significant dif-
ferences in clinical scores by time (F = 54.879, p < .001)
and treatment assignment (F = 12.249, p = .008), and inter-
action between time and treatment assignment was alsol disease scores were recorded daily until 45 days after induction. The
ay 20 from the 1st MOG (M) immunization. Apocynin (EAE + apocynin,
the entire period. Control groups also received oral Apocynin
(N) MOG immunization. a Apocynin profoundly reduced the EAE
compared with apocynin-treated group. General linear models
atment and interaction between time and treatment was also
B staining of the spinal cord shows extensive demyelination in the
letely absent in EAE mice treated with apocynin. The square area in
illustrated in the right-hand panel. Scale bar represents 50 μm
Fig. 8 Post-treatment of apocynin also ameliorates the clinical signs and disease progression of EAE. Clinical disease scores were recorded daily
until 30 days after induction. Clinical signs of EAE first appeared on day 15 and reached peak levels on day 22 from the 1st MOG (M) immunization.
Apocynin (EAE + apocynin, n = 5) or its vehicle (EAE + vehicle, n = 5) was administered orally from day 18 from the 1st MOG (M) immunization.
a Post-treatment of apocynin profoundly reduced the EAE clinical score induced by MOG. Data are mean ± sem (n = 5). *p < 0.05 compared
with apocynin-treated group. General linear models verified statistical significant differences in clinical scores by time and treatment and interaction
between time and treatment was also noticed. b Post-treatment of apocynin did not exert the incidence rate of EAE induced by MOG. c Post-treatment
of apocynin reduced MOG-induced demyelination in the spinal cord of EAE mice. Mice were sacrificed 30 days after MOG injection and sections of spinal
cord were evaluated for damaged myelin sheaths using luxol fast blue (LFB). White matter lesion was reflected by reduced LFB staining in the spinal cord.
LFB staining of the spinal cord shows extensive demyelination in the MOG-immunized EAE mice. EAE-associated demyelination was significantly reduced
in EAE mice treated with apocynin. Scale bar represents 50 μm
Choi et al. Journal of Neuroinflammation  (2015) 12:104 Page 12 of 15noticed (F = 3.824, p < .001). Apocynin treatment also de-
creased demyelination (Fig. 8c). Furthermore, this preser-
vation of the clinical score was evident until at least
30 days after the first MOG immunization.
Discussion
The present study shows that oral administration of apoc-
ynin, an NADPH oxidase assembly inhibitor, ameliorated
clinical signs of MOG-induced EAE. The attenuation of
EAE pathogenesis by apocynin was accompanied by re-
duced white matter damage, ROS production, immune
cell infiltration, and BBB disruption.
ROS are involved in the several pathogenic processes
of EAE and MS [2, 3, 30]. ROS scavenging has been
shown to decrease the severity of clinical symptoms in
EAE [2, 31, 32]. ROS damage endothelial cells of the
blood–brain barrier [33] and the myelin sheath [34, 35].
Several enzymes are capable of producing ROS, in-
cluding xanthine oxidase and NADPH oxidase. The cellsresponsible for production of ROS are believed to be
macrophages or activated microglia in the central ner-
vous system [32, 36, 37]. NADPH oxidase is a multi-
component enzyme consisting of several subunits that
coalesce at the cell membrane upon activation. NADPH
oxidase is a membrane-bound electron transfer chain in-
volving a flavocytochrome. Activation of the NADPH oxi-
dase complex is induced by a conformational change in
the flavocytochrome, which serves as a switch. Apocynin
inhibits the assembly of the cytosol and membrane-bound
components of the NADPH oxidase complex [10].
Apocynin is a cell permeable selective inhibitor of
NADPH oxidase [38] and has an approximately 1 h half-
life [39]. Apocynin has very low toxicity (LD50: 9 g/kg
upon oral administration to mice) [11], and it has been
demonstrated in past experiments that apocynin is BBB
permeable [40, 41]. Therefore, apocynin can affect both
compartments as ingested apocynin enters circulation,
can affect peripheral T cells, and also penetrates into the
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fects as it accesses both areas. A recent study also dem-
onstrated that apocynin can promote BBB integrity [42].
We delivered apocynin for entire experimental period to
prevent MOG-induced NADPH oxidase activation. We
believe that continuous administration of apocynin may
not be toxic and has a protective effect on MOG-induced
ROS production. The present study demonstrates that
apocynin not only decreased ROS production but also re-
duced the number of infiltrating cells, which were identi-
fied as CD4, CD8, CD20, and F4/80-immunopositive cells,
representing T, B, and macrophage/microglial cells, re-
spectively. This point of view is supported by previous
finding that apocynin suppressed the cytokine production
of CD8+ T cells [43]. Thus, the present study shows that
NADPH oxidase activation and subsequent ROS are
significant contributors to myelin sheath damage in EAE
mice.
Although we found that oral administration of apocynin
showed protective effects on EAE pathogenesis, the pre-
cise mechanism is still unclear. Previously, we showed that
EAE-induced white matter injury and behavioral deficits
were caused by abnormal zinc modulation. Excessive
extracellular zinc release and intracellular zinc accumula-
tion may cause a sequence of events such as MMP-9 acti-
vation, BBB disruption, immune cell infiltration, and
autophagy induction. Systemic administration of a zinc
chelator (or zinc ionophore), clioquinol, reduced MMP-9
activation, BBB disruption, immune cell infiltration, and
myelin destruction. Therefore, we suggested that modula-
tion of extracellular zinc release during EAE is involved in
myelin damage in spinal cord white matter [44]. However,
our previous study did not elucidate how extracellular zinc
causes this sequence of events involved in myelin damage.
Zinc alone induced NADPH oxidase activation in neu-
rons. Our previous study showed p47phox and p67phox sub-
unit translocation from the cytoplasm to the plasma
membrane after glucose deprivation/glucose reperfusion,
and that this translocation is prevented by zinc chelation
[5]. Zinc-induced neuronal NADPH oxidase activation in
neuronal cultures has also been demonstrated by other
groups [45, 46]. Zinc-induced ROS production was also
blocked by the hexose monophosphate shunt inhibitor, 6-
aminonicotinamide (6-AN), which limits the rate at which
NADPH can be formed [47]. Thus, the above studies sug-
gested that zinc release may be an intermediary event in
NADPH oxidase activation-induced ROS production in
several CNS injuries.
Activated microglia in the CNS has been suggested in
the pathogenesis of white matter disorders. Li et al. pre-
sented a study that peroxynitrite produced by iNOS and
NADPH oxidase in activated microglia may play an
important role in the pathogenesis of white matter disor-
ders [48]. Liu et al. demonstrated that blocking theassembly of the NADPH oxidase complex or knocking
down p47phox reduced ROS production and attenuated
neuroinflammation using isolated myelin and primary
microglia culture [49]. However, no studies have previ-
ously been performed to evaluate the protective effects of
apocynin on EAE-induced white matter damage using an
animal model. Our in vitro studies also demonstrated that
MOG induces superoxide production within the first hour
that can be markedly reduced by apocynin. Apocynin also
reduced MOG-induced microglial morphology transform-
ation, proliferation, and pro-inflammatory cytokine re-
lease, while promoted IL-4 release. It is quite possible that
the initial superoxide production initiated the changes in
microglial cytokine expression and release profile, particu-
larly because NADPH oxidase-derived superoxide produc-
tion occurs hours before changes in cytokines or in other
protein expression patterns occur. In fact, the importance
of superoxide as a mediator of macrophage phenotype
shift from M1 to M2, as well as promoting autoreactive T
cell maturation has been demonstrated by utilizing dia-
betic mice with genetic ablation in NADPH oxidase activ-
ity (Nfc1) [50, 51]. Of note, MOG failed to induce NO
release, which is a typical pro-inflammatory response, and
reflects the fact that microglial responses are very much
stimuli dependent. For instance, the pro-inflammatory
cytokine TNF-α fails to induce NO production, while LPS
does induce prominent NO release [24].
Taken together, EAE-induced white matter damage is
caused by a sequence of events such as by aberrant zinc
modulation, NADPH oxidase activation, ROS production,
and inflammatory chain reaction. In the present study, we
first demonstrate that apocynin ameliorates clinical signs
of MOG-induced EAE in mice. This amelioration was ac-
companied by inhibition of the EAE-associated demyelin-
ation and infiltration of encephalitogenic immune cells
including T cells, B cells, and microglial activation in the
spinal cord. Apocynin treatment not only reduced ROS
production and BBB breakdown but also reduced inflam-
matory chain reaction, in which NADPH oxidase activa-
tion might be one of the initial steps of EAE-induced
myelin damage. Furthermore, the present study found
that post-treatment of apocynin also decreased the clin-
ical course of EAE and magnitude of spinal cord de-
myelination. However, these results must be interpreted
with some caution as depletion of the Ncf-1 gene,
which leads to a complete loss of NADPH oxidase ac-
tivity, is seen to actually enhance EAE [52]. The differ-
ence might be due to the developmental issues lifelong
deletion of NADPH oxidase activity can cause com-
pared to the short time pharmacological inhibition of
the enzymatic activity utilized in the present study.
Therefore, treatment of multiple sclerosis via inhibition
of NADPH activation needs to be pursued with careful
consideration for the potentially adverse effects that
Choi et al. Journal of Neuroinflammation  (2015) 12:104 Page 14 of 15may arise from complete and sustained cessation of this
pathway.Conclusions
Based on the present study, our results suggest that
NADPH oxidase activation is involved in several steps of
MS pathogenesis. The amelioration of EAE progression
provided by apocynin suggests that inhibition of NADPH
oxidase activation has a high therapeutic potential to treat
multiple sclerosis.
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